These agents inhibit tumor cell proliferation and invasiveness, promote apoptosis, and reduce angiogenesis by downregulating pro-survival markers like VEGF and Bcl-2, additionally, by suppressing critical signaling pathways such as PI3K/AKT and extracellular signal-regulated kinase 1 and 2 (ERK1 and ERK2) (9, 53–55). The gene discussed is VEGFA; the disease is neoplasm.